Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Johnsen NA, Carlisle R, Baghoomian W, Pierce JL, Nguyen MO. A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified[...]

Yan MJ, Shen A, Galamgam J, Hogeling M, Cheng C. A rare case of dystrophic calcinosis cutis in an infant. JAAD Case Rep. 2025 Oct[...]

Jeong C, Chou PP, Dong E, Shen A, McKenzie S, Lane F, Smart C, Kang Y, Kasperkiewicz M, Armstrong AW. An atypical case of pemphigus[...]